Acorda Therapeutics (NASDAQ:ACOR) : Acorda Therapeutics (NASDAQ:ACOR) had a healthy money flow of $0.16 million into the stock during the Wednesdays trading session. The value of bullish trades on upticks was $0.81 million, whereas, investors only sold shares worth $0.65 million on downticks. The stock closed the day with an up-down ratio of 1.24.The money flow in the block trades to the tune of $0.01 million shows that the bulls were dominant, the large players used the weakness in the stock to accumulate it for the long-term. $0.01 million worth of transactions were on upticks. Acorda Therapeutics (NASDAQ:ACOR) stock slid $0.11 intraday and traded at 25.2, a change of -0.43% over previous days close. However, for the week, the company shares are -0.16% compared to previous weeks close.
In an insider trading activity, According to the information disclosed by the Securities and Exchange Commission in a Form 4 filing, the officer (Chief of Business Operations) of Acorda Therapeutics Inc, Lawrence David had sold 500 shares worth of $12,545 in a transaction dated June 22, 2016. In this transaction, 500 shares were sold at $25.09 per share. Currently the company Insiders own 7.6% of Acorda Therapeutics shares according to the proxy statements. In the past twelve weeks, the net percent change held by company insiders has changed by -8.91% . During last six month period, the net percent change held by insiders has seen a change of -8.91%.
The company shares have dropped -21.13% from its 1 Year high price. On Dec 31, 2015, the shares registered one year high at $43.63 and the one year low was seen on May 20, 2016. The 50-Day Moving Average price is $26.75 and the 200 Day Moving Average price is recorded at $31.86. Acorda Therapeutics (NASDAQ:ACOR): During Wednesdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $25.69 and $24.92 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $25.95. The buying momentum continued till the end and the stock did not give up its gains. It closed at $25.39, notching a gain of 0.32% for the day. The total traded volume was 497,324 . The stock had closed at $25.31 on the previous day.
Acorda Therapeutics, Inc. is a biopharmaceutical company engaged in the identification, development and commercialization of therapies that restore neurological function and treat patients with neurological disorders. The Companys markets three United States Food and Drug Administration (FDA)-approved therapies, including Ampyra (dalfampridine) Extended Release Tablets, 10milligrams, a treatment to improve walking in patients with multiple sclerosis (MS). It also markets Zanaflex Capsules and tablets, FDA-approved as short-acting drugs for the management of spasticity, and Qutenza, an FDA-approved dermal patch for the management of neuropathic pain associated with post-herpetic neuralgia, also known as post-shingles pain. The Company is also developing a number of clinical and preclinical stage therapies for the treatment of a range of disorders, including chronic post-stroke walking deficits (PSWD), Parkinsons disease, epilepsy, heart failure, MS, and spinal cord injury.